{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-011402","form_type":"8-K","ticker":"EVFM","cik":"0001618835","company_name":"Evofem Biosciences, Inc.","filed_at":"2024-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.832962+00:00","generated_at":"2026-06-04T07:10:36.450633+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Evofem posts $18.2M Phexxi net sales in 2023; operating loss improves 79% YoY; Aditxt acquisition pending","bullets":["Net product sales $18.2M, up from $16.8M in 2022; Q4 sales $4.8M vs $0.2M.","Total operating expenses reduced 64% to $36.1M from $101.0M; selling and marketing down 73%.","Loss from operations improved to $17.8M from $84.1M (79% improvement).","Entered definitive agreement to be acquired by Aditxt (ADTX); expected closing H2 2024.","Cash: $0.6M restricted at Dec 2023; compared to $2.8M unrestricted at Dec 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-011402","json":"https://secwatch.observer/filing/0001493152-24-011402.json","markdown":"https://secwatch.observer/filing/0001493152-24-011402.md","text":"https://secwatch.observer/filing/0001493152-24-011402.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618835/000149315224011402/0001493152-24-011402-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618835/000149315224011402/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T07:10:36.450633+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"188fd9bc6184de41b1209eb8966d1deeb96f2a18","claim":"Evofem Biosciences, Inc. reported year ended December 31, 2023 results: revenue $18.2 million.","evidence_excerpt":"For the year ended December 31, 2023, net product sales were $18.2 million compared to $16.8 million in net product sales in the prior year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315224011402/0001493152-24-011402-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2023"},{"label":"Revenue","value":"$18.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"54bb1352d27dd753aee66ee1e2490f78fd94c510","claim":"Evofem Biosciences, Inc. reported three months ended December 31, 2023 results: revenue $4.8 million.","evidence_excerpt":"For the three months ended December 31, 2023, net product sales were $4.8 million compared to $0.2 million in the prior year period.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315224011402/0001493152-24-011402-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended December 31, 2023"},{"label":"Revenue","value":"$4.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}